CD274 and cervical carcinoma: Pembrolizumab has been approved by the FDA for patients with recurrent or metastatic cervical cancer in progression on or after chemotherapy whose tumors were PD-L1 positive, and several interestingtrials with immune checkpoint inhibitors are currently ongoing.